|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG005813301 |
003 |
DE-627 |
005 |
20230425173341.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2022 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG005813301
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2019-003230-17-NL
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CAIN457M2301E1
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2019-003230-17-GB
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a A clinical trial to evaluate long-term treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps) and that participated in the previous clinical studies named CAIN457M2301 and CAIN457M2302.
|b A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 19-08-2020, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2022) vom: 04. Apr.
|
773 |
1 |
8 |
|g year:2022
|g day:04
|g month:04
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003230-17
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2022
|b 04
|c 04
|